Related Experiment Video

Updated: Oct 22, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K

Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer

Camille Franchet1, Jean-Sébastien Hoffmann2, Florence Dalenc3

  • 1Laboratoire de Pathologie and Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, 1 Av. Irène Joliot-Curie, 31100 Toulouse, France.

Cancers
|August 27, 2021
PubMed

Insights

Poly-(ADP)-ribose polymerase (PARP) inhibitors are vital for treating BRCA-mutated breast cancers. However, resistance limits their effectiveness, prompting research into new therapeutic strategies targeting DNA repair mechanisms.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Poly-(ADP)-ribose polymerase (PARP) inhibition demonstrates synthetic lethality with homologous recombination (HR) deficiency.
  • PARP inhibitors (PARPi) are clinically utilized for breast cancers harboring mutated BRCA1/2 HR factors.

Purpose of the Study:

  • To investigate the mechanisms of PARPi resistance in breast cancer.
  • To identify acquired vulnerabilities and novel therapeutic strategies to overcome PARPi resistance.

Main Methods:

  • Review of established and emerging resistance mechanisms to PARP inhibitors.
  • Analysis of DNA double-strand break (DSB) repair pathways and their regulation.
  • Exploration of novel treatment strategies based on identified vulnerabilities.

Main Results:

  • High rates of PARPi resistance are observed in clinical settings.
  • Multiple resistance mechanisms and acquired vulnerabilities have been identified.
  • Newly identified modes of DSB repair regulation are under investigation.

Conclusions:

  • Understanding PARPi resistance mechanisms is crucial for improving patient outcomes.
  • Novel therapeutic strategies targeting DSB repair are being developed.
  • Improving the therapeutic index of PARPi through combination therapies or novel agents is a key goal.
Keywords:
PARP inhibitorbreast cancerhomologous recombination deficiencyresistance

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.5K
Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

4.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K